Cargando…

Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas

SIMPLE SUMMARY: Chondrosarcoma is a rare bone tumor characterized by the secretion of a cartilage-like extracellular matrix. Its treatment poses major challenges, since chondrosarcoma is resistant to chemotherapy and radiotherapy. Consequently, chondrosarcoma treatment has been limited over the past...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lhuissier, Eva, Aury-Landas, Juliette, Lenté, Marion, Boumediene, Karim, Baugé, Catherine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8472299/ https://www.ncbi.nlm.nih.gov/pubmed/34572877 http://dx.doi.org/10.3390/cancers13184648

Ejemplares similares

3-Deazaneplanocin A (DZNep), an Inhibitor of the Histone Methyltransferase EZH2, Induces Apoptosis and Reduces Cell Migration in Chondrosarcoma Cells
por: Girard, Nicolas, et al.
Publicado: (2014)

Heterogeneity of chondrosarcomas response to irradiations with X-rays and carbon ions: A comparative study on five cell lines
por: Girard, Nicolas, et al.
Publicado: (2020)

Evaluation of the impact of S-adenosylmethionine-dependent methyltransferase inhibitor, 3-deazaneplanocin A, on tissue injury and cognitive function in mice
por: Lhuissier, Eva, et al.
Publicado: (2018)

3-Deazaneplanocin A (DZNep), an Inhibitor of S-Adenosylmethionine-dependent Methyltransferase, Promotes Erythroid Differentiation
por: Fujiwara, Tohru, et al.
Publicado: (2014)

Identification of an easy to use 3D culture model to investigate invasion and anticancer drug response in chondrosarcomas
por: Lhuissier, Eva, et al.
Publicado: (2017)

Anti-inflammatory and chondroprotective effects of the S-adenosylhomocysteine hydrolase inhibitor 3-Deazaneplanocin A, in human articular chondrocytes
por: Aury-Landas, Juliette, et al.
Publicado: (2017)

Functional Characterization of D9, a Novel Deazaneplanocin A (DZNep) Analog, in Targeting Acute Myeloid Leukemia (AML)
por: Jiang, Xia, et al.
Publicado: (2015)

Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells
por: Xie, Zhigang, et al.
Publicado: (2011)

EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin
por: Chen, Si-qi, et al.
Publicado: (2020)

DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis
por: Sha, Mingquan, et al.
Publicado: (2015)

DZNep promotes mouse bone defect healing via enhancing both osteogenesis and osteoclastogenesis
por: Cao, Xiankun, et al.
Publicado: (2021)

Sleep and Neurochemical Modulation by DZNep and GSK-J1: Potential Link With Histone Methylation Status
por: Murillo-Rodríguez, Eric, et al.
Publicado: (2019)

Combination of AZD3463 and DZNep Prevents Bone Metastasis of Breast Cancer by Suppressing Akt Signaling
por: He, Wenxin, et al.
Publicado: (2021)

Modulation of Allogeneic CD8(+) T-Cell Response by DZNep Controls GVHD While Preserving Hematopoietic Chimerism
por: Wang, Jina, et al.
Publicado: (2013)

Induction of macrophage-like immunosuppressive cells from common marmoset ES cells by stepwise differentiation with DZNep
por: Tsuji, Hyuma, et al.
Publicado: (2020)

Genome-wide analysis revealed that DZNep reduces tubulointerstitial fibrosis via down-regulation of pro-fibrotic genes
por: Mimura, Imari, et al.
Publicado: (2018)

Modulation of Skin Inflammatory Response by Active Components of Silymarin
por: Juráňová, Jana, et al.
Publicado: (2018)

DZNep inhibits H3K27me3 deposition and delays retinal degeneration in the rd1 mice
por: Zheng, Shijie, et al.
Publicado: (2018)

Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model
por: Akpa, Chidimma Agatha, et al.
Publicado: (2020)

Histone Methylation Inhibitor DZNep Ameliorated the Renal Ischemia-Reperfusion Injury via Inhibiting TIM-1 Mediated T Cell Activation
por: Li, Jiawei, et al.
Publicado: (2020)

A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep
por: Li, Yansheng, et al.
Publicado: (2019)

Low-Dose 5-Aza and DZnep Alleviate Acute Graft-Versus-Host Disease With Less Side Effects Through Altering T-Cell Differentiation
por: Wang, Qing Ya, et al.
Publicado: (2022)

Nicotine associated breast cancer in smokers is mediated through high level of EZH2 expression which can be reversed by methyltransferase inhibitor DZNepA
por: Kumari, Kanchan, et al.
Publicado: (2018)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
por: Akpa, Chidimma Agatha, et al.
Publicado: (2019)

Dznep, a histone modification inhibitor, inhibits HIF1α binding to TIMP2 gene and suppresses TIMP2 expression under hypoxia
por: Yamazaki, Tomotaka, et al.
Publicado: (2023)

DZNep, an inhibitor of the histone methyltransferase EZH2, suppresses hepatic fibrosis through regulating miR-199a-5p/SOCS7 pathway
por: Ding, Rongrong, et al.
Publicado: (2021)

Anti-inflammatory effects of an injectable copolymer of fatty acids (Ara 3000 beta®) in joint diseases
por: Baugé, Catherine, et al.
Publicado: (2015)

S-adenosylmethionine-dependent methyltransferase inhibitor DZNep blocks transcription and translation of SARS-CoV-2 genome with a low tendency to select for drug-resistant viral variants
por: Kumar, Ram, et al.
Publicado: (2022)

Description of Joint Alterations Observed in a Family Carrying p.Asn453Ser COMP Variant: Clinical Phenotypes, In Silico Prediction of Functional Impact on COMP Protein and Stability, and Review of the Literature
por: Rochoux, Quitterie, et al.
Publicado: (2021)

Epigenetically Reprogramming of Human Embryonic Stem Cells by 3-Deazaneplanocin A and Sodium Butyrate
por: Azghadi, Soheila, et al.
Publicado: (2011)

A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A
por: Zeybel, Müjdat, et al.
Publicado: (2017)

EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis
por: Allas, Lyess, et al.
Publicado: (2020)

Epigenetic Abnormalities in Chondrosarcoma
por: Bereza, Michał, et al.
Publicado: (2023)

Use of Adult Stem Cells for Cartilage Tissue Engineering: Current Status and Future Developments
por: Baugé, Catherine, et al.
Publicado: (2015)

Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
por: Chen, Siqi, et al.
Publicado: (2022)

Chondrosarcoma: biology, genetics, and epigenetics
por: Chow, Warren A
Publicado: (2018)

3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
por: Ni, Jun, et al.
Publicado: (2019)

Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche
por: Gaudichon, Jérémie, et al.
Publicado: (2014)

Correction: 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression
por: Ni, Jun, et al.
Publicado: (2019)

TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells
por: Baugé, Catherine, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nhpranta1jgkd3qemdkdaq3m0u